Arch Therapeutics Announces Notice of Allowance for Composition-of-Matter Patent Covering Self-Assembling Peptides
05 avr. 2016 07h57 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Apr 5, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use in...
Arch Therapeutics Obtains Favorable Safety Data for AC5 Surgical Hemostatic Device(TM) in Skin Irritation Testing in Humans
22 mars 2016 07h57 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Mar 22, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ ("AC5™"), reports...
Arch Therapeutics Reports Favorable Results for AC5 Surgical Hemostatic Device in Biocompatibility Testing Required for CE Mark
14 mars 2016 07h57 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Mar 14, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ ("AC5™"), has obtained...
Arch Therapeutics to Present at the 28th Annual Roth Capital Conference on Tuesday, March 15, 2016
10 mars 2016 08h20 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Mar 10, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use in...
Arch Therapeutics Receives ISO 13485 Certification for AC5
09 mars 2016 07h57 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Mar 9, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ ("AC5™"), today announces...
Arch Therapeutics Clinical Trial Actively Enrolling Patients and Providing Investigational Treatment
07 mars 2016 07h57 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Mar 7, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ ("AC5™"), has initiated...
Arch Therapeutics to Present at the SeeThruEquity Annual Innovations Investor Conference in Miami, Florida on Monday, February 22, 2016
17 févr. 2016 07h57 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Feb 17, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use in...
Arch Therapeutics to Present at the Source Capital Group's 2016 Disruptive Growth & Healthcare Conference on Wednesday, February 10, 2016
08 févr. 2016 07h57 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Feb 8, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use in...
Arch Therapeutics to Present at the BIO CEO & Investor Conference on Monday, February 8, 2016
03 févr. 2016 07h57 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Feb 3, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use in...
Arch Therapeutics to Present at the Biotech Showcase(TM) 2016 Conference on January 12th 2016
04 janv. 2016 07h57 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Jan 4, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of the AC5 Surgical Hemostatic Device™...